

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Integrated Pathways of Disease in NASH and NAFLD (A4)

January 20-24, 2019 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA

Scientific Organizers: Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 2, 2018 / Abstract Deadline: October 24, 2018 / Discounted Registration Deadline: November 27, 2018

### SUNDAY, JANUARY 20

#### Arrival and Registration

### MONDAY, JANUARY 21

#### Welcome and Keynote Address

**Gökhan S. Hotamisligil**, Harvard University, USA  
*Metainflammation and Fatty Liver Disease*

#### Genetic / Ethnic Determinants and Natural History of NAFLD

**Stefano Romeo**, University of Gothenburg, Sweden  
*Genetic Drivers of NAFLD*

**Arun J. Sanyal**, Virginia Commonwealth University Medical Center, USA

*The Dynamic Nature of NAFLD: A Critical Analysis of Disease Progression and Regression*

**Vincent WS Wong**, Chinese University of Hong Kong, Hong Kong  
*NAFLD across the World – Similarities and Differences*

#### Short Talk(s) Chosen from Abstracts

#### Workshop 1: Biomarkers

##### Short Talks Chosen from Abstracts

#### Metabolic Drivers of Cell Stress and Injury

**Harmeet Malhi**, Mayo Clinic, USA  
*Lipotoxic Stress and the Pathogenesis of NASH*

**Michael Trauner**, Medical University of Vienna, Austria  
*Bile Acid Regulation of Metabolism in the Development and Progression of NAFLD*

**Johan Auwerx**, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland  
*Systems Biology*

#### Short Talk Chosen from Abstracts

#### Poster Session 1

### TUESDAY, JANUARY 22

#### Drivers and Consequences of Hepatic Lipotoxicity in NAFLD

**Brent A. Tetri**, Saint Louis University, USA  
*Fatty Acid Dysregulation in NAFLD*

**Petra Hirsova**, Mayo Clinic, USA  
*Death Receptor Signaling and Cell Injury NASH*

**Sheila Collins**, Vanderbilt University Medical Center, USA  
*Thermogenesis and Energy Utilization*

#### Speaker to be Announced

#### Short Talk(s) Chosen from Abstracts

#### Workshop 2: Therapeutics

##### Short Talks Chosen from Abstracts

#### Innate Immune and Inflammatory Signaling

**Gyongyi Szabo**, University of Massachusetts Medical School, USA  
*Innate Immune Cell Activation in NASH: Mechanisms and Therapeutic Targets*

**Wajahat Z. Mehal**, Yale University, USA  
*Innate Immune Signaling and NASH*

**Dean A. Falb**, Synlogic, USA  
*Synthetic Biology and Microbiome Signaling*

#### Short Talk Chosen from Abstracts

#### Poster Session 2

### WEDNESDAY, JANUARY 23

#### Integrative and Systemic Biology of NAFLD

**Thomas P. Burris**, St. Louis University School of Medicine, USA  
*Targeting Orphan Nuclear Receptors for Treatment of NASH*

**Li Li**, Icahn School of Medicine at Mount Sinai, USA  
*Therapeutic Stratification of Patients with NASH and NAFLD Based on Phenomic Profiles from Electronic Medical Data*

**Ira Tabas**, Columbia University, USA  
*Adipocyte Biology*

#### Speaker to be Announced

#### Short Talk(s) Chosen from Abstracts

#### Fibrosis and Cancer – Mechanisms and Markers

**Scott L. Friedman**, Icahn School of Medicine at Mount Sinai, USA  
*Stellate Cell Biology*

**Jelena Mann**, Newcastle University, UK  
*Epigenetics of Fibrosis and Cancer in Liver Disease*

**Chinweike Ukomadu**, Novartis Institutes for Biomedical Research, USA

*Addressing New Molecular Targets for the Treatment of NASH*

#### Short Talk Chosen from Abstracts

#### Poster Session 3

### THURSDAY, JANUARY 24

#### Modalities of NAFLD Diagnosis and Prognosis Assessment

**Tina S. Nova**, Molecular Stethoscope, USA  
*Biomarkers and NASH*

#### Speaker to be Announced

**Rohit Loomba**, University of California, San Diego, USA  
*Serum and Imaging Biomarkers*

**Sangeeta N. Bhatia**, Massachusetts Institute of Technology, USA  
*Assessing Matrix Turnover and Proteolysis*

#### Speaker to be Announced

#### Short Talk(s) Chosen from Abstracts

#### Workshop 3: Animal Models

##### Short Talks Chosen from Abstracts

#### Clinical Trial Design and Emerging Therapies

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Integrated Pathways of Disease in NASH and NAFLD (A4)

January 20-24, 2019 • Eldorado Hotel & Spa • Santa Fe, New Mexico, USA

Scientific Organizers: Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 2, 2018 / Abstract Deadline: October 24, 2018 / Discounted Registration Deadline: November 27, 2018

**Mary E. Rinella**, Northwestern University, USA

*Clinical Trial Design, Endpoints and Regulatory Science in NAFLD  
Accelerating Patient Accrual and Shortening Trial Length*

**Christopher R. Shepard**, Evo Bio

*mRNA Therapeutics*

**Geoffrey von Maltzahn**, Seres Therapeutics, USA

*Microbiome Therapeutics*

**Meeting Wrap-Up: Outcomes and Future Directions (Organizers)**

**FRIDAY, JANUARY 25**

**Departure**